Efficacy News and Research

RSS

How soy and gut microbes alter cancer treatment results

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary components, especially soy compounds processed by gut bacteria, can alter drug metabolism and impact treatment outcomes.

2 Jun 2025

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

2 Jun 2025

Flea protein inspires breakthrough in preventing medical implant infections

A protein that gives fleas their bounce has been used to boot out bacteria cells, with lab results demonstrating the material's potential for preventing medical implant infection.

2 Jun 2025

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

2 Jun 2025

New combination treatment offers hope for immune checkpoint blockade resistant skin cancers

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.

2 Jun 2025

Expert review reveals how to fuel triathletes for optimal results

This systematic review synthesizes evidence from 35 studies to guide optimal nutrition, supplementation, and recovery for triathletes. The findings highlight the critical importance of glycogen balance, hydration, targeted supplementation, and ongoing education—especially for female athletes at risk of energy deficiency.

2 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

Navigating the challenges and progress in dengue vaccine development

Dengue fever caused by a flavivirus named DENV is a major global health challenge, risking almost half of the world's population. Since the early 20th century, the scientific community has faced multiple challenges to develop effective dengue vaccines.

30 May 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025

LUCAS technology revolutionizes rapid viral diagnostics

Mass General Brigham researchers are shining a powerful new light into the viral darkness with the development of Luminescence CAscade-based Sensor (LUCAS), a rapid, portable, highly-sensitive diagnostic tool for processing complex biological samples.

30 May 2025

Early allergen introduction reduces childhood food allergy risk

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic treatments in managing allergic conditions.

29 May 2025

Traditional Kava rituals provide alternative pathway to PTSD recovery

Researchers reviewed pilot and qualitative evidence suggesting that combining traditional Pacific kava with talanoa dialogue may help reduce PTSD symptoms among Pacific veterans and first responders. A clinical trial is planned to formally evaluate the safety, efficacy, and cultural adaptability of this innovative, culturally grounded therapy.

29 May 2025

Advanced organoid model recreates complex liver architecture

The liver has a unique structure, especially at the level of individual cells. Hepatocytes, the main liver cells, release bile into tiny channels called bile canaliculi, which drain into the bile duct in the liver periportal region.

29 May 2025

Early measles vaccination gains urgency amid global outbreak

The global measles outbreak must trigger an urgent debate into whether a vaccine should be recommended earlier to better protect against the highly contagious disease during infancy, a new review states.

29 May 2025

Immune system shows unique signature in Parkinson's patients

Parkinson's disease is best known for its effects on the central nervous system. In addition, recent scientific advances generally emphasize the role of the immune system in the presence and development of the disease.

28 May 2025

Non-drug therapies show real promise in calming agitation in Alzheimer’s

Non-drug therapies like music and light outperform medications in managing dementia-related agitation, enhancing patient care and safety for caregivers.

28 May 2025

New injection therapy can lead to long lasting blood pressure reduction

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that giving people with high blood pressure an injection every six months can lead to a meaningful, sustained reduction in their blood pressure.

28 May 2025

Oral 8-aminoguanine protects aging eyes and preserves vision in preclinical study

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly reducing oxidative stress and inflammation. These findings highlight the promise of 8-AG as a non-invasive intervention to slow age-related retinal degeneration.

27 May 2025